Summary

The global pharmaceutical manufacturing equipment market size is projected to grow from USD 19.41 billion in 2024 to USD 26.94 billion in 2029, recording a CAGR of 6.8% during the forecast period. Rising demand for generic drugs is driving the growth of the pharmaceutical manufacturing equipment market. Whereas the demand for refurbished equipments is restraining the growth of the pharmaceutical manufacturing equipment market.

“Packaging machines segment is expected to witness highest CAGR during the forecasted period in pharmaceutical manufacturing equipment market.”
The packaging machines segment is expected to have the highest CAGR in the pharmaceutical manufacturing equipment market due to a few critical factors. Innovative drug delivery formats such as pre-filled syringes, single-dose vials, and blister packs are gaining much importance in the pharmaceutical industry, which requires advanced and sophisticated packaging solutions. In addition, adoption of sophisticated packaging technologies, such as serialization and tamper-evident solutions, is stringent regulatory requirements for drug safety and traceability. It is also due to the growing trend of patient-centric healthcare, where packaging is playing an important role in enhancing user convenience and compliance. The growth in biologics, personalized medicines, and vaccines also requires highly precise and sterile packaging environments, thereby further driving demand for advanced packaging machines.

"Liquid segment is likely to witness highest CAGR in pharmaceutical manufacturing equipment market during forecasted period .”
The liquid segment is witnessing the CAGR due to regulatory emphasis on pediatric formulations. Regulatory bodies such as the US Food and Drug Administration (FDA) have stressed the need for age-appropriate liquid medications to address the challenges children face with swallowing solid forms like tablets and capsules. This push ensures better compliance, safety, and efficacy in pediatric treatments, significantly driving demand for liquid dosage forms. Additionally, liquid medications allow precise dosing, making them ideal for children and other patients requiring tailored administration. The growing focus on pediatric health has led pharmaceutical companies to innovate in liquid formulations, opening new market opportunities.

“Europe is expected to hold the second largest market share of the pharmaceutical manufacturing equipment market during forecasted period”.
The region is marked by a very competitive landscape, dominated by both large pharmaceutical companies and SMEs, thus facilitating innovation and diversification in terms of products. A tremendous investment in R&D for new manufacturing technologies supports the region's dominance in this market. Biopharmaceuticals form a great shift in the industry and have transformed it across Europe; Germany has emerged to be the largest producer of EU-approved biopharmaceutical substances. This growth is matched by increasing revenues from biologics, which further strengthens the the pharmaceutical manufacturing equipment market in Europe.

Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

• By Company Type - Tier 1 – 40%, Tier 2 – 35%, Tier 3 – 25%
• By Designation— C-level Executives - 45%, Directors - 35%, Others - 20%
• By Region—North America - 30%, Europe - 25%, Asia Pacific - 40%, RoW - 5%

The pharmaceutical manufacturing equipment market is dominated by a few globally established players such as GEA Group Aktiengesellschaft (Germany), I.M.A. INDUSTRIA MACCHINE AUTOMATICHE S.P.A. (Italy), Syntegon Technology GmbH (Germany), Romaco Group (Germany), ACG (India), Körber AG (Germany), Thermo Fisher Scientific Inc. (US), Marchesini Group (Italy), MG2 s.r.l (Italy), Glatt GmbH (Germany). The study includes an in-depth competitive analysis of these key players in the pharmaceutical manufacturing equipment market, with their company profiles, recent developments, and key market strategies.

Research Coverage:
The report segments the pharmaceutical manufacturing equipment and forecasts its size by equipment type, end product type, and region. The report also discusses the drivers, restraints, opportunities, and challenges pertaining to the market. It gives a detailed view of the market across four main regions—North America, Europe, Asia Pacific, and RoW. Supply chain analysis has been included in the report, along with the key players and their competitive analysis in the pharmaceutical manufacturing equipment ecosystem.

Key Benefits to Buy the Report:
• Analysis of key drivers (Rising demand for pharmaceuticals, technological advancements in equipment and growing implementation & adoption of regulatory guidelines). Restraint (Demand for refurbished equipment), Opportunity (Growth in personalized medicines), Challenges (Rising costs and expenditures related to usage of pharmaceutical manufacturing equipment).
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the pharmaceutical manufacturing equipment market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the pharmaceutical manufacturing equipment market across varied regions
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the pharmaceutical manufacturing equipment market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players GEA Group Aktiengesellschaft (Germany), I.M.A. INDUSTRIA MACCHINE AUTOMATICHE S.P.A. (Italy), Syntegon Technology GmbH (Germany), Romaco Group (Germany), ACG (India) among others in the pharmaceutical manufacturing equipment market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 27
1.3 STUDY SCOPE 27
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 27
1.3.2 INCLUSIONS AND EXCLUSIONS 28
1.3.3 YEARS CONSIDERED 28
1.4 CURRENCY CONSIDERED 28
1.5 UNIT CONSIDERED 29
1.6 STAKEHOLDERS 29
1.7 LIMITATIONS 29
1.8 SUMMARY OF CHANGES 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
2.1.1 SECONDARY DATA 31
2.1.1.1 List of key secondary sources 31
2.1.1.2 Key data from secondary sources 31
2.1.2 PRIMARY DATA 32
2.1.2.1 List of primary interview participants 32
2.1.2.2 Breakdown of primaries 32
2.1.2.3 Key data from primary sources 33
2.1.2.4 Key industry insights 33
2.1.3 SECONDARY AND PRIMARY RESEARCH 34
2.2 MARKET SIZE ESTIMATION METHODOLOGY 34
2.2.1 BOTTOM-UP APPROACH 36
2.2.1.1 Approach to arrive at market size through bottom-up analysis (demand side) 36
2.2.2 TOP-DOWN APPROACH 37
2.2.2.1 Approach to arrive at market size through top-down analysis (supply side) 37
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 38
2.4 RESEARCH ASSUMPTIONS 39
2.5 RESEARCH LIMITATIONS 39
2.6 RISK ANALYSIS 40
3 EXECUTIVE SUMMARY 41
 
4 PREMIUM INSIGHTS 44
4.1 ATTRACTIVE GROWTH OPPORTUNITIES FOR PLAYERS IN PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET 44
4.2 PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET, BY EQUIPMENT TYPE 45
4.3 PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET, BY END-PRODUCT TYPE 45
4.4 PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET, BY COUNTRY 46
5 MARKET OVERVIEW 47
5.1 INTRODUCTION 47
5.2 MARKET DYNAMICS 47
5.2.1 DRIVERS 48
5.2.1.1 Growing rate of chronic diseases 48
5.2.1.2 Adoption of modular manufacturing setups 48
5.2.1.3 Increasing implementation and adoption of regulatory guidelines 48
5.2.2 RESTRAINTS 50
5.2.2.1 Rising adoption of refurbished equipment 50
5.2.3 OPPORTUNITIES 50
5.2.3.1 Growing demand for personalized medicines 50
5.2.3.2 Rising demand for biopharmaceuticals 51
5.2.4 CHALLENGES 51
5.2.4.1 Adherence to multiple regulations and standards 51
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 52
5.4 PRICING ANALYSIS 53
5.4.1 INDICATIVE PRICING OF KEY PLAYERS, BY EQUIPMENT TYPE, 2023 53
5.4.2 AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL PACKAGING MACHINES, 2019–2023 54
5.4.3 AVERAGE SELLING PRICE TREND, BY REGION, 2019–2023 55
5.5 VALUE CHAIN ANALYSIS 56
5.6 ECOSYSTEM ANALYSIS 58
5.7 IMPACT OF AI/GENERATIVE AI ON PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET 59
5.8 TECHNOLOGY ANALYSIS 60
5.8.1 KEY TECHNOLOGIES 60
5.8.1.1 Digital twin 60
5.8.1.2 Automation and robotics 60
5.8.1.3 IoT 61
5.8.2 COMPLEMENTARY TECHNOLOGIES 61
5.8.2.1 3D printing 61
5.8.3 ADJACENT TECHNOLOGIES 61
5.8.3.1 CAD and CAM 61
5.9 PATENT ANALYSIS 62
5.10 TRADE ANALYSIS 64
5.10.1 IMPORT DATA (HS CODE 842230) 64
5.10.2 EXPORT DATA (HS CODE 842230) 65
5.11 KEY CONFERENCES AND EVENTS, 2025–2026 66
5.12 CASE STUDIES 67
5.12.1 ZAMBON COMPANY S.P.A. AND IMA ACTIVE COLLABORATED ON PROCESS OPTIMIZATION PROJECT TO ENHANCE BATCH CONSISTENCY AND QUALITY 67
5.12.2 ACG HELPED INDIAN PHARMACEUTICAL COMPANY RETROFIT B MAX MACHINE WITH NITROGEN-ENHANCED PURGING SYSTEM 68
5.12.3 SYNTEGON PROVIDED JIANGSU WITH AIM 5022S PLATFORM TO ENHANCE INSPECTION EFFICIENCY AND ACCURACY 68
5.13 REGULATIONS LANDSCAPE 69
5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
5.13.2 STANDARDS 71
5.14 PORTER'S FIVE FORCES ANALYSIS 72
5.14.1 BARGAINING POWER OF SUPPLIERS 73
5.14.2 BARGAINING POWER OF BUYERS 73
5.14.3 THREAT OF NEW ENTRANTS 73
5.14.4 THREAT OF SUBSTITUTES 73
5.14.5 INTENSITY OF COMPETITIVE RIVALRY 74
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 74
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 74
5.15.2 BUYING CRITERIA 75
6 PHARMACEUTICAL MANUFACTURING EQUIPMENT SUPPLIERS AND AFTERMARKET SUPPLIERS 76
6.1 INTRODUCTION 76
6.2 ORIGINAL EQUIPMENT MANUFACTURERS 76
6.3 AFTERMARKET SUPPLIERS 77
7 MAJOR PHARMACEUTICAL EQUIPMENT MANUFACTURING PROCESSES 78
7.1 INTRODUCTION 78
7.2 FORMULATION PROCESS 79
7.3 TABLETING AND ENCAPSULATION PROCESS 79
7.4 ASEPTIC PROCESS 80
7.5 PACKAGING PROCESS 80
7.6 QUALITY CONTROL PROCESS 80
8 END USERS OF PHARMACEUTICAL MANUFACTURING EQUIPMENT 82
8.1 INTRODUCTION 82
8.2 PHARMACEUTICAL MANUFACTURING COMPANIES 82
8.3 CONTRACT MANUFACTURING ORGANIZATIONS 83
9 PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET,
BY END-PRODUCT TYPE 84
9.1 INTRODUCTION 85
9.2 SOLID 86
9.2.1 ONGOING TECHNOLOGICAL INNOVATIONS TO DRIVE MARKET 86
9.3 LIQUID 88
9.3.1 RISING APPLICATION FOR UNSTABLE DRUGS IN SOLID FORM
TO BOOST DEMAND 88
10 PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET, BY EQUIPMENT TYPE 90
10.1 INTRODUCTION 91
10.2 PACKAGING MACHINES 93
10.2.1 RISING NEED TO ENSURE PROTECTION AGAINST DAMAGE AND CONTAMINATION TO FUEL MARKET GROWTH 93
10.3 FILLING MACHINES 97
10.3.1 GROWING NEED FOR COMPLIANCE WITH STRINGENT REGULATORY STANDARDS TO FOSTER MARKET GROWTH 97
10.4 SPRAY DRYING EQUIPMENT 101
10.4.1 PRESSING NEED TO PRODUCE HIGH-QUALITY DRUG PRODUCTS TO FUEL MARKET GROWTH 101
10.5 MIXING AND BLENDING MACHINES 104
10.5.1 ABILITY TO PROVIDE CONTROLLED AND CONSISTENT AGITATION AND SHEAR FORCES TO ENSURE HOMOGENEITY OF DRUG FORMULATION TO BOOST DEMAND 104
10.6 MILLING EQUIPMENT 108
10.6.1 RISING NEED TO REDUCE PARTICLE SIZE OF DRUG FORMULATIONS TO FOSTER MARKET GROWTH 108
10.7 EXTRUSION EQUIPMENT 112
10.7.1 ELEVATING USE TO PRODUCE VARIOUS DOSAGE FORMS TO FUEL MARKET GROWTH 112
10.8 TABLET COMPRESSION PRESSES 115
10.8.1 INCREASING PREFERENCE FOR SOLID DOSAGE FORMS TO DRIVE MARKET 115
10.9 INSPECTION EQUIPMENT 119
10.9.1 SURGING NEED TO ENSURE QUALITY AND INTEGRITY OF DRUG PRODUCTS TO FOSTER MARKET GROWTH 119
10.10 GRANULATION EQUIPMENT 123
10.10.1 ABILITY TO IMPROVE OVERALL STABILITY AND BIOAVAILABILITY OF DRUGS TO BOOST DEMAND 123
10.11 STERILIZATION EQUIPMENT 126
10.11.1 GROWING DEMAND FOR CONTAMINATION-FREE DRUGS AND PRODUCTS TO DRIVE MARKET 126
 
11 PHARMACEUTICAL MANUFACTURING EQUIPMENT MARKET, BY REGION 130
11.1 INTRODUCTION 131
11.2 NORTH AMERICA 133
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 133
11.2.2 US 136
11.2.2.1 Government-led initiatives to advance pharmaceutical manufacturing capacity to drive market 136
11.2.3 CANADA 138
11.2.3.1 Rising emphasis on strengthening domestic manufacturing capabilities to foster market growth 138
11.2.4 MEXICO 139
11.2.4.1 Increasing focus on streamlining pharmaceutical regulatory processes to fuel market growth 139
11.3 EUROPE 141
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 141
11.3.2 UK 143
11.3.2.1 Rising emphasis on developing advanced manufacturing equipment to offer lucrative growth opportunities 143
11.3.3 GERMANY 145
11.3.3.1 Escalating demand for branded and generic drugs to foster market growth 145
11.3.4 FRANCE 146
11.3.4.1 Government-led policies to encourage investment and innovation in pharmaceutical manufacturing industry to accelerate demand 146
11.3.5 ITALY 148
11.3.5.1 Growing focus on establishing pharmaceutical manufacturing facilities to create significant growth opportunities 148
11.3.6 REST OF EUROPE 149
11.4 ASIA PACIFIC 151
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 151
11.4.2 CHINA 154
11.4.2.1 Surging FDIs and regulatory reforms to streamline drug approvals to offer lucrative growth opportunities 154
11.4.3 JAPAN 156
11.4.3.1 Increasing demand for innovative pharmaceutical manufacturing solutions to fuel market growth 156
11.4.4 INDIA 157
11.4.4.1 Government-led initiatives to strengthen domestic manufacturing to boost demand 157
11.4.5 SOUTH KOREA 159
11.4.5.1 Low import tariffs and enhanced regulatory transparency to attract foreign investments to foster market growth 159
11.4.6 REST OF ASIA PACIFIC 160
 
11.5 ROW 161
11.5.1 MACROECONOMIC OUTLOOK FOR ROW 161
11.5.2 MIDDLE EAST 164
11.5.2.1 Expanding pharmaceutical manufacturing infrastructure to offer growth opportunities 164
11.5.2.2 GCC 164
11.5.2.3 Rest of Middle East 164
11.5.3 AFRICA 166
11.5.3.1 Rising investment in local pharmaceutical manufacturing to fuel market growth 166
11.5.4 SOUTH AMERICA 166
11.5.4.1 Introduction of tax incentives to strengthen pharmaceutical manufacturing to support market growth 166
12 COMPETITIVE LANDSCAPE 167
12.1 OVERVIEW 167
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2024 167
12.3 REVENUE ANALYSIS, 2019–2023 169
12.4 MARKET SHARE ANALYSIS, 2023 169
12.5 COMPANY VALUATION AND FINANCIAL METRICS, 2024 172
12.6 BRAND/PRODUCT COMPARISON 174
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 175
12.7.1 STARS 175
12.7.2 EMERGING LEADERS 175
12.7.3 PERVASIVE PLAYERS 175
12.7.4 PARTICIPANTS 175
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 177
12.7.5.1 Company footprint 177
12.7.5.2 Region footprint 178
12.7.5.3 Primary packaging equipment footprint 179
12.7.5.4 Secondary packaging equipment footprint 180
12.7.5.5 Type footprint 181
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 182
12.8.1 PROGRESSIVE COMPANIES 182
12.8.2 RESPONSIVE COMPANIES 182
12.8.3 DYNAMIC COMPANIES 182
12.8.4 STARTING BLOCKS 182
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 184
12.8.5.1 Detailed list of key startups/SMEs 184
12.8.5.2 Competitive benchmarking of key startups/SMEs 184
12.9 COMPETITIVE SCENARIO 185
12.9.1 PRODUCT LAUNCHES 185
12.9.2 DEALS 186
13 COMPANY PROFILES 187
13.1 KEY PLAYERS 187
13.1.1 GEA GROUP AKTIENGESELLSCHAFT 187
13.1.1.1 Business overview 187
13.1.1.2 Products/Solutions/Services offered 189
13.1.1.3 Recent developments 190
13.1.1.3.1 Product launches 190
13.1.1.3.2 Deals 190
13.1.1.4 MnM view 191
13.1.1.4.1 Key strengths/Right to win 191
13.1.1.4.2 Strategic choices 191
13.1.1.4.3 Weaknesses/Competitive threats 191
13.1.2 I.M.A INDUSTRIA MACCHINE AUTOMATICHE S.P.A. 192
13.1.2.1 Business overview 192
13.1.2.2 Products/Solutions/Services offered 193
13.1.2.3 Recent developments 194
13.1.2.3.1 Deals 194
13.1.2.4 MnM view 194
13.1.2.4.1 Key strengths/Right to win 194
13.1.2.4.2 Strategic choices 195
13.1.2.4.3 Weaknesses/Competitive threats 195
13.1.3 SYNTEGON TECHNOLOGY GMBH 196
13.1.3.1 Business overview 196
13.1.3.2 Products/Solutions/Services offered 197
13.1.3.3 Recent developments 197
13.1.3.3.1 Product launches 197
13.1.3.3.2 Deals 198
13.1.3.3.3 Expansions 199
13.1.3.4 MnM view 199
13.1.3.4.1 Key strengths/Right to win 199
13.1.3.4.2 Strategic choices 199
13.1.3.4.3 Weaknesses/Competitive threats 199
13.1.4 ACG 200
13.1.4.1 Business overview 200
13.1.4.2 Products/Solutions/Services offered 200
13.1.4.3 Recent developments 201
13.1.4.3.1 Deals 201
13.1.4.3.2 Expansions 202
13.1.4.4 MnM view 202
13.1.4.4.1 Key strengths/Right to win 202
13.1.4.4.2 Strategic choices 202
13.1.4.4.3 Weaknesses/Competitive threats 202
13.1.5 THERMO FISHER SCIENTIFIC INC. 203
13.1.5.1 Business overview 203
13.1.5.2 Products/Solutions/Services offered 205
13.1.5.3 Recent developments 205
13.1.5.3.1 Deals 205
13.1.5.3.2 Expansions 206
13.1.5.4 MnM view 207
13.1.5.4.1 Key strengths/Right to win 207
13.1.5.4.2 Strategic choices 207
13.1.5.4.3 Weaknesses/Competitive threats 207
13.1.6 ROMACO GROUP 208
13.1.6.1 Business overview 208
13.1.6.2 Products/Solutions/Services offered 209
13.1.6.3 Recent developments 210
13.1.6.3.1 Product launches 210
13.1.6.3.2 Deals 210
13.1.7 KÖRBER AG 211
13.1.7.1 Business overview 211
13.1.7.2 Products/Solutions/Services offered 212
13.1.7.3 Recent developments 213
13.1.7.3.1 Deals 213
13.1.7.3.2 Expansions 214
13.1.8 MARCHESINI GROUP S.P.A. 215
13.1.8.1 Business overview 215
13.1.8.2 Products/Solutions/Services offered 215
13.1.8.3 Recent developments 216
13.1.8.3.1 Product launches 216
13.1.8.3.2 Deals 217
13.1.9 MG2 S.R.L. 218
13.1.9.1 Business overview 218
13.1.9.2 Products/Solutions/Services offered 218
13.1.9.3 Recent developments 220
13.1.9.3.1 Product launches 220
13.1.10 GLATT GMBH 221
13.1.10.1 Business overview 221
13.1.10.2 Products/Solutions/Services offered 221
13.2 OTHER PLAYERS 222
13.2.1 BAUSCH+STRÖBEL SE + CO. KG 222
13.2.2 COPERION GMBH 223
13.2.3 ELIZABETH COMPANIES 224
13.2.4 FETTE COMPACTING 225
13.2.5 FREUND 226
13.2.6 KORSCH AG 227
13.2.7 L.B. BOHLE MASCHINEN UND VERFAHREN GMBH 228
13.2.8 LFA MACHINES 229
13.2.9 CVC TECHNOLOGIES, INC. 230
13.2.10 OHARA TECHNOLOGIES 231
13.2.11 PRISM PHARMA MACHINERY 232
13.2.12 SAINTYCO 233
13.2.13 SILVERSON 234
13.2.14 YENCHEN MACHINERY CO., LTD 234
13.2.15 QUALICAPS 235
13.2.16 COESIA S.P.A. 236
13.2.17 UHLMANN 237
13.2.18 AUTOMATED SYSTEMS OF TACOMA, LLC 238
14 APPENDIX 239
14.1 INSIGHTS FROM INDUSTRY EXPERTS 239
14.2 DISCUSSION GUIDE 240
14.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 243
14.4 CUSTOMIZATION OPTIONS 245
14.5 RELATED REPORTS 245
14.6 AUTHOR DETAILS 246